Revance Therapeutics Gets Permanent J-Code for Daxxify
By Chris Wack
Revance Therapeutics said Friday that the U.S. Centers for Medicare & Medicaid Services has assigned a permanent J-code for Daxxify, indicated for the treatment of cervical dystonia in adults.
J-Codes are product-specific reimbursement codes used by commercial insurance plans, Medicare, and other government payers and are intended to simplify reimbursement for providers and expand access for patients.
The Food and Drug Administration approved Daxxify for the treatment of cervical dystonia in August 2023.
The Phase 3 clinical study showed that Daxxify was shown to be effective, generally safe, and well tolerated across two dose groups.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
February 02, 2024 08:31 ET (13:31 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
After Earnings, Is Alphabet Stock a Buy, a Sell, or Fairly Valued?
-
When Will the Fed Start Cutting Interest Rates?
-
What’s the Difference Between the CPI and PCE Indexes?
-
Powell Unfazed By Sticky Inflation, but Rate Cuts Are Far Off
-
After Earnings, Is Microsoft Stock a Buy, a Sell, or Fairly Valued?
-
Best- and Worst-Performing Stocks of April 2024
-
Magnificent 7 Stocks Earnings Updates: AI Remains the Focus
-
Small-Cap and Value Stocks Are Undervalued
-
4 Utility Stocks to Benefit from Data Center Growth
-
Albemarle Earnings: We Expect Improved Results In the Rest of Year Following Cyclically Low Profits
-
Novo Nordisk Earnings: Raised Fair Value Estimate Still a Contrast to Market Overenthusiasm
-
After Earnings, Is Verizon Stock a Buy, a Sell, or Fairly Valued?
-
Look Inside Berkshire Hathaway’s Portfolio Before Its Annual Meeting
-
How to Invest Like Warren Buffett
-
Cognizant Earnings: Improved Profitability Buttresses Results as Customer Spending Remains Muted
-
10 Top-Performing Dividend Stocks of the Month